摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

isobutyl-quinazolin-4-yl-amine | 22754-09-2

中文名称
——
中文别名
——
英文名称
isobutyl-quinazolin-4-yl-amine
英文别名
N-(2-methylpropyl)quinazolin-4-amine
isobutyl-quinazolin-4-yl-amine化学式
CAS
22754-09-2
化学式
C12H15N3
mdl
MFCD02943319
分子量
201.271
InChiKey
VYWCYZSHFOVZJY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    37.8
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • CD4-MIMETIC INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF
    申请人:Dana-Farber Cancer Institute, Inc.
    公开号:US20140350113A1
    公开(公告)日:2014-11-27
    Described herein are small-molecule mimics of CD4, which both enter the Phe43 cavity and target Asp368 of gp120, the HIV-1 envelope protein. Also described herein are methods of using these compounds to inhibit the transmission or progression of HIV infection. These compounds exhibit antiviral potency greater than that of a known antiviral, NBD-556, with 100% breadth against clade B and C viruses. Importantly, the compounds do not activate HIV infection of CD4-negative, CCR5-positive cells, in contrast to NBD-556.
    本文描述了CD4的小分子模拟物,它们进入Phe43腔并靶向HIV-1包膜蛋白gp120的Asp368。本文还描述了使用这些化合物抑制HIV感染的传播或进展的方法。这些化合物表现出比已知抗病毒药物NBD-556更强的抗病毒效力,对B和C类病毒具有100%的广度。重要的是,与NBD-556相比,这些化合物不会激活CD4阴性,CCR5阳性细胞的HIV感染。
  • CD4-MIMETIC SMALL MOLECULES SENSITIZE HUMAN IMMUNODEFICIENCY VIRUS TO VACCINE-ELICITED ANTIBODIES
    申请人:MADANI Navid
    公开号:US20160362478A1
    公开(公告)日:2016-12-15
    Described herein are methods of generating a protein binding domain that specifically binds to gp120 in a specific conformational state, comprising contacting gp120 with a CD4-mimetic compound, thereby forming gp120 in the specific conformational state; and generating antibodies to gp120 in the specific conformation state. Relatedly, the disclosure also describes methods of neutralizing HIV-1, comprising contacting HIV-1 with an effective amount of a CD4-mimetic compound, thereby forming HIV-1 having gp120 in a specific conformational state; and contacting the HIV-1 in the specific conformational state with an antibody.
  • US9403763B2
    申请人:——
    公开号:US9403763B2
    公开(公告)日:2016-08-02
查看更多